The remaining two variants included one upstream variant at the MSMB locus that was annotated as pathogenic for hereditary prostate cancer, as well as one stop-gain variant within DUOXA2 that was annotated as pathogenic for thyroid dyshormonogenesis. Here, DUOXA2 is linked to prostate cancer.